7th Jun 2023 12:05
RUA Life Sciences PLC - Glasgow-based medical technology holding company - Expects to report year-on-year revenue growth of 34% for the year ended on March 31, with revenue of GBP2.2 million produced from Contract Manufacture, GBP1.6 million, and Biomaterials, GBP554,000. Expects pretax loss to be similar to last year at around GBP2.3 million to GBP2.4 million. For financial 2022, revenue was GBP1.6 million and pretax loss was GBP2.4 million.
Chair Bill Brown says: "RUA has a portfolio of four businesses, all of which have made good progress during the period. The mature businesses are growing revenue and generating attractive net margins and the development business segments of Vascular and Structural Heart have made good regulatory and technological progress respectively on relatively low levels of investment."
Current stock price: 43.00 pence each, up 7.5% on Wednesday midday in London
12-month change: down 1.2%
By Xindi Wei, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Rua Life Sci.